Number of the records: 1
Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy.
- 1.
SYSNO ASEP 0578397 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy. Author(s) Táborská, P. (CZ)
Lukáč, Pavol (MBU-M) ORCID, RID
Stakheev, Dmitry (MBU-M)
Rajsiglová, Lenka (MBU-M) ORCID
Kalkusová, K. (CZ)
Strnadová, K. (CZ)
Lacina, L. (CZ)
Dvořánková, B. (CZ)
Novotný, Jiří (UMG-J) ORCID
Kolář, Michal (UMG-J) RID, ORCID
Vraná, M. (CZ)
Čechová, H. (CZ)
Ransdorfová, S. (CZ)
Valerianová, M. (CZ)
Smetana Jr., K. (CZ)
Vannucci, Luca (MBU-M) RID, ORCID
Smrž, Daniel (MBU-M)Source Title Scientific Reports. - : Nature Publishing Group - ISSN 2045-2322
Roč. 13, November (2023), s. 19079Number of pages 20 s. Language eng - English Country US - United States Keywords B7-H1 Antigen ; Histiocytoma ; Immunotherapy ; ligand ; programmed death 1 ligand 1 ; malignant fibrous histiocytoma ; cell line ; nude mouse OECD category Immunology R&D Projects NU23-08-00071 GA MZd - Ministry of Health (MZ) LX22NPO5102 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) LM2018129 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) EF18_046/0016045 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) Method of publishing Open access Institutional support MBU-M - RVO:61388971 ; UMG-J - RVO:68378050 UT WOS 001099663700027 EID SCOPUS 85175859406 DOI 10.1038/s41598-023-46305-7 Annotation Soft tissue sarcomas are aggressive mesenchymal-origin malignancies. Undifferentiated pleomorphic sarcoma (UPS) belongs to the aggressive, high-grade, and least characterized sarcoma subtype, affecting multiple tissues and metastasizing to many organs. The treatment of localized UPS includes surgery in combination with radiation therapy. Metastatic forms are treated with chemotherapy. Immunotherapy is a promising treatment modality for many cancers. However, the development of immunotherapy for UPS is limited due to its heterogeneity, antigenic landscape variation, lower infiltration with immune cells, and a limited number of established patient-derived UPS cell lines for preclinical research. In this study, we established and characterized a novel patient-derived UPS cell line, JBT19. The JBT19 cells express PD-L1 and collagen, a ligand of the immune checkpoint molecule LAIR-1. JBT19 cells can form spheroids in vitro and solid tumors in immunodeficient nude mice. We found JBT19 cells induce expansion of JBT19-reactive autologous and allogeneic NK, T, and NKT-like cells, and the reactivity of the expanded cells was associated with cytotoxic impact on JBT19 cells. The PD-1 and LAIR-1 ligand-expressing JBT19 cells show ex vivo immunogenicity and effective in vivo xenoengraftment properties that can offer a unique resource in the preclinical research developing novel immunotherapeutic interventions in the treatment of UPS. Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2024 Electronic address https://www.nature.com/articles/s41598-023-46305-7
Number of the records: 1